Management of Corneal Graft Rejection – A Case Series Report and Review of the Literature

Nguyẽ̂n, Phó̂; Barte, Felise May; Shinada, Shuntaro; Yiu, Samuel C.

doi:10.4172/2155-9570.1000103

Cited by 13 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found only one study, with a limited number of participants, on the systemic use of Aza [43]. Triple therapy with Aza, oral prednisone, and CsA was used successfully in three high-risk corneal transplant patients prior to regrafting.…”

Section: Azathioprine (Aza)mentioning

confidence: 99%

Literature review and suggested protocol for prevention and treatment of corneal graft rejection

Magalhaes

Bardan

Zarei-Ghanavati

et al. 2019

Eye

View full text Add to dashboard Cite

Effective prophylaxis and treatment of corneal graft rejection are essential to improve outcomes in corneal transplantation. To date, there has been no standardized protocol published that outlines the optimal prophylactic and therapeutic approaches and, furthermore, the published controlled trials on this subject are limited. Likewise, no study has addressed how the level of antigen exposure varies between different types of keratoplasties. The aim of this paper is to provide a simple evidencebased protocol for the prevention and treatment of corneal graft rejection.

show abstract

Section: Azathioprine (Aza)mentioning

confidence: 99%

Literature review and suggested protocol for prevention and treatment of corneal graft rejection

Magalhaes

Bardan

Zarei-Ghanavati

et al. 2019

Eye

View full text Add to dashboard Cite

show abstract

“… 1 Immunosuppressive strategies in the high risk group has helped in reducing this rejection rate, although repeat keratoplasty is often needed. 2 The success of repeat keratoplasty depends on the number of previous failed surgeries, an indication for keratoplasty and the approach used for keratoplasty. 3 - 5 In view of sparing availability of donor material, judicious use of corneal tissue especially in failed keratoplasties is a matter of concern.…”

mentioning

confidence: 99%

Outcome of repeat penetrating keratoplasty in eyes with failed penetrating keratoplasty

Khairallah

2016

SMJ

View full text Add to dashboard Cite

Objectives:To report the outcomes of penetrating keratoplasty (PKP) surgeries in eyes with failed PKP.Methods:This was a retrospective, non-comparative, descriptive case series. Thirty eyes of 30 patients with failed PKP comprised our study group, they were reviewed from January 2007 to December 2012 at the King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia. Data were collected on best corrected visual acuity before and after one week, one month, 3 months, 6 months, one year, and 2 years following PKP. Intraoperative and postoperative complications, changes in intraocular pressure (IOP), additional surgical procedure and other ocular comorbidities were also documented. The visual outcomes at 6 months and one year were associated with risk factors.Results:Before intervention, 18 (60%) eyes had vision <20/400. Vision was 20/20 to 20/60 in 10 (30%) eyes at 6 months, 17 (57%) eyes at 12 months, and 22 (73%) eyes at 24 months. The variation in IOP at different follow up periods was not significant (p=0.2). The presence of other ocular comorbidity was not significantly associated with functional visual outcome (p=0.4). Additional surgical procedure after repeat PKP enabled a regain of excellent vision in 9 (47%) eyes at one year. The numbers for past corneal surgeries were significantly associated with the visual outcome at 6 months.Conclusion:Penetrating keratoplasty to manage failed PKP resulted in reducing visual disabilities.

show abstract

“…A case study taking 5 patients suggests that systemic immune suppression with 2 or more agents may be helpful to prevent corneal graft rejection [2] in high-risk patients.…”

Section: Therapies In Ophthalmologymentioning

confidence: 99%

Salient Features of New Therapies in Ophthalmology

Nayak¹

2011

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

Although glaucoma is a leading cause of blindness worldwide, yet there are no large databases where risk factors, current management options and outcomes may be evaluated. With this concept in mind, Dallas Glaucoma Registry [4] was established to focus on an ethnically mixed North Texas population. Large numbers of patients in the ongoing Dallas Glaucoma Registry do provide adequate data to better understand risk factors, early detection, improved screening targets, treatment options, outcomes and future studies.A case study was done to evaluate the choroidal thickness changes in the eyes with myopic choroidal neovascularization [5] (mCNV) after AbstractThis review gives the information regarding the therapies that are used against ophthalmological disorders and along with that it helps us to update ourselves to know more about the salient features of the therapies, drugs and diagnosis methodologies. This review also shares information regarding the various eye related diseases like substantial changes in corneal structure, glaucoma, cataract and age-related macular degeneration and many other and along with that the remedial therapies like Refractive laser surgery, in Polypoidal Choroidal Vasculopathy (PCV), Ranibizumab and Panretinal laser photocoagulation etc.

show abstract

Management of Corneal Graft Rejection – A Case Series Report and Review of the Literature

Cited by 13 publications

References 30 publications

Literature review and suggested protocol for prevention and treatment of corneal graft rejection

Literature review and suggested protocol for prevention and treatment of corneal graft rejection

Outcome of repeat penetrating keratoplasty in eyes with failed penetrating keratoplasty

Salient Features of New Therapies in Ophthalmology

Contact Info

Product

Resources

About